Company Announces Exit from Resolve mdx Business, Anticipates Restructuring Charges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy MDXH?
As part of its Q1 results announcement last night, the company stated: "On April 20, 2026, the Company received a Medicare contractor recoupment decision from Novitas Solutions totaling approximately $10.4 million related to a retrospective review of certain historical Resolve mdx claims. The Company strongly disagrees with the contractor's findings and is vigorously contesting the contractor's decision on substantive and procedural grounds. Management has evaluated the matter and concluded that the recognition criteria for an accrual have not been met. The existence and ultimate amount of any obligation are contingent on the outcomes of a multi-level appeals process, which are uncertain future events not wholly within the Company's control. At this time no reliable estimate of any obligation can be made. Accordingly, the matter is accounted for as a contingent liability, and no provision has been recorded for the first quarter ended March 31, 2026. On May 8, 2026, the Company approved a strategic plan to exit the Resolve mdx business, including the cessation of operations at its laboratory facility in Plano, Texas. As a result of this decision, the Company expects to incur restructuring and other exit-related charges in connection with the wind-down. These charges are expected to consist principally of (i) employee severance and other termination benefits, (ii) charges associated with the Plano facility lease, including accelerated amortization of the right-of-use asset and leasehold improvements, (iii) impairment of long-lived assets associated with the Resolve mdx business, including capitalized assets and equipment, (iv) charges relating to the disposition or termination of vendor and supplier contracts, and (v) other exit-related costs. The amount and timing of these charges has not been finalized and will be determined and recognized in accordance with applicable IFRS in future periods as the wind-down is executed and additional information becomes available." Shares are down 40% in pre-market at $1.19.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDXH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDXH
Wall Street analysts forecast MDXH stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.985
Low
7.00
Averages
7.67
High
9.00
Current: 0.985
Low
7.00
Averages
7.67
High
9.00
About MDXH
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MDxHealth SA Q1 Earnings Report Analysis
- Disappointing Earnings: MDxHealth SA reported a Q1 GAAP EPS of -$0.17, missing expectations by $0.02, indicating ongoing pressure on profitability that may affect investor confidence.
- Lackluster Revenue Growth: Revenue increased by 12.7% year-over-year to $27.38M, yet fell short of expectations by $3.42M, reflecting unmet market demand that could pose challenges for future performance.
- Declining Gross Margin: Gross margins decreased from 63.8% last year to 60.7%, a drop of 3.1 percentage points primarily due to changes in test mix, indicating pressure on cost control that may impact overall profitability.
- Rising Operating Expenses: Operating expenses rose by 19% to $23.9M year-over-year, driven mainly by increased headcount and other costs related to the ExoDx acquisition, highlighting the financial burden faced during the company's expansion efforts.
See More
MDxHealth SA Reports Q4 Earnings Miss
- Earnings Report Disappointment: MDxHealth SA's Q4 GAAP EPS of -$0.17 missed expectations by $0.04, indicating challenges in profitability that could undermine investor confidence moving forward.
- Lackluster Revenue Growth: The company reported Q4 revenue of $29.5 million, a 19.4% year-over-year increase, yet it fell short of expectations by $1.33 million, reflecting intensified market competition and potential shortcomings in sales strategies.
- Future Sales Outlook: MDxHealth anticipates FY25 net sales of up to $109 million, suggesting growth potential; however, confidence in achieving this target may be dampened by the current underperformance.
- Quant Rating Analysis: Seeking Alpha's Quant Rating on MDxHealth indicates a cautious market sentiment regarding its future performance, which may lead to diminished investor interest in the stock in the short term.
See More
Mdxhealth to Present 2025 Financial Results and Corporate Update
- Earnings Release Schedule: Mdxhealth will release its financial results for Q4 and the full year ended December 31, 2025, after market close on February 26, 2026, indicating the company's ongoing development in the precision diagnostics sector.
- Conference Call Details: The company will host a conference call on February 26, 2026, at 4:30 PM ET, featuring a live Q&A session aimed at enhancing investor engagement and transparency.
- Webcast Information: The webcast will be accessible 15 minutes prior to the call, with a replay available post-event on the company’s website, ensuring that investors who cannot attend live can still access critical information.
- Company Background: Mdxhealth is a leading precision diagnostics firm focused on providing actionable molecular information to personalize patient diagnosis and treatment, primarily targeting urologic cancers and related diseases, showcasing its expertise and technological advantages in the healthcare field.
See More
MDxHealth Reports $109M Revenue for 2025, Projects 26%-28% Growth for 2026
- Significant Revenue Growth: MDxHealth expects fourth-quarter 2025 revenue of approximately $30.5 million, a 23% increase from $24.7 million in Q4 2024, indicating continued double-digit growth across its precision diagnostics portfolio.
- Full-Year Performance Boost: Projected full-year revenue for 2025 is $109 million, up 21% from $90 million in 2024, reflecting strong market performance and increased customer demand.
- Successful Product Transition: In 2025, the company sold 71,920 liquid-based units, a 57% increase, while tissue-based units totaled 49,180, up 18%, demonstrating the successful integration of the Exosome Diagnostics business.
- Optimistic Future Outlook: MDxHealth issued 2026 revenue guidance of $137 million to $140 million, representing expected growth of 26% to 28%, while aiming for a 10% adjusted EBITDA margin run rate by the end of 2026, showcasing confidence in sustained growth.
See More
MDxHealth Files Shelf Registration to Sell Up to $200 Million in Shares
- Financing Plan: MDxHealth has filed a shelf registration to sell up to $200 million in shares, including $50 million in preferred stock, aimed at strengthening the company's capital structure to support future growth.
- Market Reaction: This stock issuance plan may influence investor perceptions of the company's future financial health, potentially leading to short-term stock price volatility, but ultimately enhancing liquidity in the long run.
- Strategic Significance: By raising funds, MDxHealth can increase investments in research and development, particularly in the precision medicine sector, thereby enhancing its market competitiveness and driving business expansion.
- Investor Focus: The market will closely monitor the specific uses of this financing and its potential impact on the company's future performance, especially in the context of increasing competition in the healthcare industry.
See More
BTIG Reaffirms Buy Rating on MDxHealth, Increases Price Target to $7
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information that help traders succeed in the stock market.
See More
MDxHealth SA Q1 Earnings Report Analysis
- Disappointing Earnings: MDxHealth SA reported a Q1 GAAP EPS of -$0.17, missing expectations by $0.02, indicating ongoing pressure on profitability that may affect investor confidence.
- Lackluster Revenue Growth: Revenue increased by 12.7% year-over-year to $27.38M, yet fell short of expectations by $3.42M, reflecting unmet market demand that could pose challenges for future performance.
- Declining Gross Margin: Gross margins decreased from 63.8% last year to 60.7%, a drop of 3.1 percentage points primarily due to changes in test mix, indicating pressure on cost control that may impact overall profitability.
- Rising Operating Expenses: Operating expenses rose by 19% to $23.9M year-over-year, driven mainly by increased headcount and other costs related to the ExoDx acquisition, highlighting the financial burden faced during the company's expansion efforts.
See More
MDxHealth SA Reports Q4 Earnings Miss
- Earnings Report Disappointment: MDxHealth SA's Q4 GAAP EPS of -$0.17 missed expectations by $0.04, indicating challenges in profitability that could undermine investor confidence moving forward.
- Lackluster Revenue Growth: The company reported Q4 revenue of $29.5 million, a 19.4% year-over-year increase, yet it fell short of expectations by $1.33 million, reflecting intensified market competition and potential shortcomings in sales strategies.
- Future Sales Outlook: MDxHealth anticipates FY25 net sales of up to $109 million, suggesting growth potential; however, confidence in achieving this target may be dampened by the current underperformance.
- Quant Rating Analysis: Seeking Alpha's Quant Rating on MDxHealth indicates a cautious market sentiment regarding its future performance, which may lead to diminished investor interest in the stock in the short term.
See More
Mdxhealth to Present 2025 Financial Results and Corporate Update
- Earnings Release Schedule: Mdxhealth will release its financial results for Q4 and the full year ended December 31, 2025, after market close on February 26, 2026, indicating the company's ongoing development in the precision diagnostics sector.
- Conference Call Details: The company will host a conference call on February 26, 2026, at 4:30 PM ET, featuring a live Q&A session aimed at enhancing investor engagement and transparency.
- Webcast Information: The webcast will be accessible 15 minutes prior to the call, with a replay available post-event on the company’s website, ensuring that investors who cannot attend live can still access critical information.
- Company Background: Mdxhealth is a leading precision diagnostics firm focused on providing actionable molecular information to personalize patient diagnosis and treatment, primarily targeting urologic cancers and related diseases, showcasing its expertise and technological advantages in the healthcare field.
See More
MDxHealth Reports $109M Revenue for 2025, Projects 26%-28% Growth for 2026
- Significant Revenue Growth: MDxHealth expects fourth-quarter 2025 revenue of approximately $30.5 million, a 23% increase from $24.7 million in Q4 2024, indicating continued double-digit growth across its precision diagnostics portfolio.
- Full-Year Performance Boost: Projected full-year revenue for 2025 is $109 million, up 21% from $90 million in 2024, reflecting strong market performance and increased customer demand.
- Successful Product Transition: In 2025, the company sold 71,920 liquid-based units, a 57% increase, while tissue-based units totaled 49,180, up 18%, demonstrating the successful integration of the Exosome Diagnostics business.
- Optimistic Future Outlook: MDxHealth issued 2026 revenue guidance of $137 million to $140 million, representing expected growth of 26% to 28%, while aiming for a 10% adjusted EBITDA margin run rate by the end of 2026, showcasing confidence in sustained growth.
See More
MDxHealth Files Shelf Registration to Sell Up to $200 Million in Shares
- Financing Plan: MDxHealth has filed a shelf registration to sell up to $200 million in shares, including $50 million in preferred stock, aimed at strengthening the company's capital structure to support future growth.
- Market Reaction: This stock issuance plan may influence investor perceptions of the company's future financial health, potentially leading to short-term stock price volatility, but ultimately enhancing liquidity in the long run.
- Strategic Significance: By raising funds, MDxHealth can increase investments in research and development, particularly in the precision medicine sector, thereby enhancing its market competitiveness and driving business expansion.
- Investor Focus: The market will closely monitor the specific uses of this financing and its potential impact on the company's future performance, especially in the context of increasing competition in the healthcare industry.
See More
BTIG Reaffirms Buy Rating on MDxHealth, Increases Price Target to $7
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information that help traders succeed in the stock market.
See More
